Date and Time
Tuesday Mar 28, 2017
7:45 AM - 9:30 AM EDT
Tuesday, March 28, 2017
7:45 a.m. - 9:30 a.m.
Location
101 Main Street - Cloud City room, 14th Floor Cambridge, MA
Fees/Admission
Free
Description
To an early-stage life science project, leveraging means more than just yields and returns. It can often mean the difference between a successful project and one that never gets to commercialization.
Join ArcPoint Strategy Life Sciences for a roundtable discussion that will examine how to apply the art of leverage to your organization and help navigate a project through tough obstacles ahead. We'll discuss ways to streamline the development process, effectively organize teams, and, of course, interface effectively with investors. You'll hear how the Strategic Alliances team at the Novartis Institutes for Biomedical Research has been able to effectively advance technology development through their collaborations, and exchange ideas with other experienced life science experts on:
- How to build a “Dream Team” by leveraging expertise and knowledge across and outside your organization
- How to leverage efficiencies in product development and stay on track to reach value creation milestones
- How to recognize nuances in the life science market and leverage important market-drivers to your competitive advantage
- How to build an IP Picket Fence to help leverage existing intellectual capital and help strengthen your market position
Roundtable Moderator:
Dr. J. Michael Delmage has over 25 years of experience in the pharmaceutical, biotechnology, and medical-device industries where he has successfully brought promising products to market. Dr. Delmage served as President and CEO at Transvivo Inc., where in just two years he developed and obtained Federal Drug Administration and CE Mark Approvals for the Omni-DL system, a miniaturized portable dialysis system that supports all current acute dialysis treatments, apheresis and Continuous Renal Replacement Therapies. Previously, he worked at Senetek PLC as Chief Technology Officer, overseeing development of the company's aesthetics, medical devices and therapeutics, as well as Santen International, where he was one of three founding executives who built the 500-person pharmaceutical firm.
